^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Besponsa (inotuzumab ozogamicin) (DNA replication inhibitor, CD22-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Besponsa is indicated as monotherapy...refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    BESPONSA is a CD22-directed antibody-drug conjugate (ADC) indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    REGIMENS FOR RELAPSED OR REFRACTORY Ph-NEGATIVE B-ALL…Other Recommended Regimens...Inotuzumab ozogamicin + mini-hyperCVD for B-ALL (cyclophosphamide, dexamethasone, vincristine, methotrexate, cytarabine)
    Secondary therapy:
    Mini-HCVD
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ...for patients with R/R Ph-negative precursor B-cell ALL, recommended category 1 options include blinatumomab or InO.
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Cancer
    Title:

    Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study

    Excerpt:
    The median overall survival (OS) was 7.7 months with InO and 6.2 months with SoC, with 2-year OS rates of 22.8% and 10.0%, respectively (overall hazard ratio, 0.75; 97.5% confidence interval [CI], 0.57-0.99; 1-sided P = .0105).
    DOI:
    10.1002/cncr.32116
    Trial ID:
    INO-VATE